With a large diabetic and pre-diabetic population, GLP-1 therapies are gaining acceptance as dual-purpose treatments
It was initially approved for adults only but has since been approved for people aged 12 or older
Eyelid Lift (Blepharoplasty) The eyes are central to a vibrant, approachable appearance
The authors highlighted the diverse, but significant, ways the 4,000+ patients responded to the medication: 88% of participants lost 5% of body weight or more
Liraglutide (Saxenda) another GLP-1 receptor agonist, recommended by NICE (TA664) for use in specialist weight management services under defined eligibility criteria, including BMI thresholds and the presence of weight-related comorbidities
Because it has no interactions with the nervous system it does not cause excitability or desensitization.+ These statements have not been evaluated by the Food and Drug Administration